设为首页|加入收藏|英文版

总体介绍

首页 > 广东省中医药科学院 > 总体介绍

中医药防治非小细胞肺癌临床与基础研究团队

2017/7/6 10:39:18字号:T|T

 

中医药防治非小细胞肺癌临床与基础研究团队是在中医基础理论的指导下,进行中医药防治非小细胞肺癌及中医药对分子靶向药物的增敏、减毒增效、逆转耐药的临床及基础研究,现拥有肿瘤分子生物学及中医药靶向治疗研究室”。Clinical and basic research team of prevention and treatment on non-small cell lung cancer with     TCM carry out academic study under the guidance of the basic theory of TCM. With the integration of Chinese and western medicine therapy theory, we proceed to the clinical and basic research of effects of TCM on sensitization, attenuated synergies and reversing drug resistance of the molecular targeted drugs. We have the laboratory of Molecular biology of the tumor and targeted therapy combined with traditional Chinese medicine.

一、团队主攻方向Main direction

1、中医药对靶向药物治疗晚期非小细胞肺癌(NSCLC)的增敏、增效减毒及逆转耐药研究

主要开展中药扶正抗癌方对吉非替尼治疗EGFR基因非突变型晚期NSCLC的增敏的临床研究、扶正抗癌方对吉非替尼治疗EGFR基因突变型晚期NSCLC的减毒、增效的临床研究、扶正抗癌方对吉非替尼治疗NSCLC的增敏作用机制的实验研究、扶正抗癌方对吉非替尼逆转耐药机制的体内及体外实验研究We carry out the clinical research of sensitization effects of TCM“Fuzheng Kang’ai decoctionFZKA )on advanced NSCLC patients harbouring mutations in the epidermal growth factor receptor (EGFR) gene treated with Gefitinib. We also carry out the clinical study of the attenuated synergies influence of FZKA on advanced NSCLC patients without mutations in the EGFR gene treated with Gefitinib. In vivo and in vitro experiments are carrying out to reveal the mechanism of effects of FZKA on attenuated synergies and reversing drug resistance of the molecular targeted drugs.

2、非小细胞肺癌中医辨证分型与西医分子病理分型的相关性研究

主要开展非小细胞肺癌寒热分型与EGFR基因状态相关性的研究,并以此为基础,有点及面,开展中医辨证分型与西医分子病理分型的相关性研究,建立中医辨证分型与西医分子病理分型相关性的网状模型。We are now carrying out the study to identify the relationship between the Yin-cold or Yang-heat TCM syndrome type and the EGFR gene status as well as efficacy of EGFR-TKIs in NSCLC patients. We found that patients with Yin-cold TCM syndrome type have more chance with sensitive EGFR gene mutation. Based on the resultswe have designed another study to identify the relationship between the TCM syndrome types and the molecular pathological types in NSCLC patients, as well as the network model between the two types.

3、中医药及中医药联合靶向药物和免疫治疗对晚期非小细胞肺癌生存影响的临床研究

主要开展晚期非小细胞肺癌患者采用单纯中医药(消积饮)治疗生存影响的作用机制,为进一步新药临床前发提供依据,及中医药联合靶向药物和免疫治疗对生存影响的作用机制,为进一步优化晚期小细胞肺癌的治疗方案提供临床和基础研究证据。We are now carrying out the study to identify the mechanism of survival of advanced NSCLC patients by using pure Chinese medicine(Xiao-ji Decoction) , to provide a research basis of new drugs, to identify the mechanism of quality of life by using Chinese medicine,TKIs and immunotherapy , as well as the foundation of the optimized treatment of advanced NSCLC patients.

二、团队负责人 Primary investigator of the team(PI)


Professor Wu Wanyin, chief physician, Ph.D. tutor, chief director of Dept. of oncology, was mainly responsible for 1 national natural science fund projects, 1 provincial project, 1 Ministry of health and 1Ministry of Civil Affairs study projects respectively. He was awarded the second prize of Science and Technology from Guangzhou University of TCM for three times. He has published more than 130 papers (4 for SCI) in international journals and has co-edited 10 academic books on oncology.

吴万垠主任医师,教授,医学博士后,博士研究生导师。广东省中医院肿瘤大科主任国家肿瘤重点专科负责人。世界中医药联合会肿瘤外治专业委员会副会长;世界中医药联合会肿瘤微创治疗专业委员会副会长广东省中医药学会肿瘤治疗与康复专业委员会副主任委员国家自然科学基金、广东省自然科学评审专家。参与主持国家“九五”、“十五”、“十一五”科技攻关课题。主持国家自然科学基金、广东省自然科学基金卫生部、民政部科研课题各1项。获广州中医药大学科技进步二等奖3项广东省科教文卫“医德标兵”。国内外发表医学论文130余篇SCI 4篇),主编及参编肿瘤专著10部


学术带头人 Academic leaders


Professor Zhang Haibo, chief physician, director of Dept. of oncology, a member of Chinese Society of Clinical Oncology (CSCO) and 7 other academic societies, was mainly responsible for 1 national and 7 provincial study projects. He was awarded the second prize of Science and Technology from Guangzhou University of TCM for twice. He has published more than 20 papers (3 for SCI) in international journals and has co-edited 4 academic books on oncology.

张海波:主任医师,广东省中医院大德路总院肿瘤科主任.中国临床肿瘤协会会员,广东省医院协会肿瘤分子靶向治疗专业委员会副主任委员,中国老年学会老年肿瘤专业委员会执行委员,中华中医药学会中医肿瘤专业委员会委员,广东省中医药肿瘤专业委员会常委,广东省中西医结合肿瘤专业委员。主持国家级课题1项,省部级及厅局级课题7项,获广州中医药大学科技技术二等奖2项。发表论文20余篇(SCI 3篇),编写专著4部。

Professor Liuning Li, chief physician, director of Dept. of oncology, a member of Chinese Society of Clinical Oncology (CSCO), successor of academic and experiences of Liu Weisheng and other 8 academic societies. She was mainly responsible for 8 provincial study projects. She has published more than 10 papers in chinese core journal and has co-edited 3 academic books on oncology.

李柳宁:主任医师,广东省中医院大学城医院肿瘤科主任,全国老中医药专家刘伟胜教授学术经验继承人。广东省中医药学会肿瘤专业委员会副主任委员,广州抗癌协会分子靶向治疗专业委员会副主任委员,世界中联肿瘤专业委员会理事会理事,世界中联肿瘤经方专业委员会理事会常务理事,中华中医药学会名医学术思想研究分会常务委员。主持省部级3项,厅局级课题5项,主编专著3部发表中文核心刊论文10余篇。

三、标志性成果

承担课题

任务来源

级别

负责人

经费

(万元)

扶正抗癌方对吉非替尼治疗非小细胞肺癌增敏作用的研究

国家自然科学基金委员会

国家级

吴万垠

70

非小细胞肺癌中医寒热分型与表皮生长因子受体(EGFR)的相关性研究

国家自然科学基金委员会

国家级

张海波

72

中药参麦注射液联合TP方案化疗对晚期非小细胞肺癌血管内皮生长因子及临床疗效的影响

广东省科技厅

省部级

李柳宁

5

 

发表论文

期刊

影响

因子

第一

作者

通讯作者

Fuzheng Kang’ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial

Trial.2015,16:146

2.117

杨小兵

吴万垠

Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer

Cancer Immunology Immunotherapy,2013,62(10):1629-1635

3.637

朱燕娟

张海波













首页|网站地图|法律申明|友情链接|招聘信息|供应商管理|名老中医学术交流|中医健康管理|中医医案管理 |知识管理|在线考试